Sermorelin vs Egrifta (Tesamorelin): Head-to-Head Efficacy Compared
HealthRX.com
Only tesamorelin has adult visceral fat trial data
Key numbers
- 15.2%Visceral fat change on tesamorelin versus placebo in the pivotal HIV adult trialSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 8, 2026
- 2 mgTesamorelin daily dose used in the pivotal HIV adult trialSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 8, 2026
- 8.0 cm/yrMean height velocity in children with growth hormone deficiency at 6 months on sermorelinSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 8, 2026
- 1.4 mgCurrent once-daily labeled dose of tesamorelin in the Egrifta SV formulationSource: dailymed.nlm.nih.gov, as cited Nov 8, 2026
From the public record
Sermorelin and tesamorelin: how much is registered
The two are nearly even on registrations, 27 for sermorelin and 24 for tesamorelin, but sermorelin has more phase 3 studies, 4 against 2. Tesamorelin has 3 recruiting now and 14 completed.
| Measure | Value |
|---|---|
| sermorelin: registered studies | 27 |
| tesamorelin: registered studies | 24 |
| sermorelin: recruiting now | 1 |
| tesamorelin: recruiting now | 3 |
| sermorelin: completed | 21 |
| tesamorelin: completed | 14 |
| sermorelin: phase 3 studies | 4 |
| tesamorelin: phase 3 studies | 2 |
How this was calculated
We looked up sermorelin and tesamorelin one after the other in the ClinicalTrials.gov intervention field, saved all matching records, and counted them by recruitment status and phase.
Registered studies naming sermorelin or tesamorelin as an intervention, any condition and status
Sermorelin's 21 completed studies against 14 for tesamorelin show history, not outcome. A phase 3 label does not mean the study backed the drug.
From the public record
Published papers on sermorelin and tesamorelin
Sermorelin's 25 papers trail tesamorelin's 96, and the gap holds for 2016 to 2025 (14 against 40). In 2025 sermorelin had 1 and tesamorelin 4.
| Measure | Value |
|---|---|
| sermorelin: papers, all years | 25 |
| tesamorelin: papers, all years | 96 |
| sermorelin: papers, 2016 to 2025 | 14 |
| tesamorelin: papers, 2016 to 2025 | 40 |
| sermorelin: papers in 2025 | 1 |
| tesamorelin: papers in 2025 | 4 |
How this was calculated
We ran one PubMed title and abstract search for sermorelin and one for tesamorelin, then recorded all-years, 2016 to 2025 and 2025 counts. Study type and quality were not filtered.
Papers naming sermorelin or tesamorelin in the title or abstract, all article types and species
Fewer sermorelin papers means less written about it, not a weaker result. Both totals mix human trials with animal, cell and review papers.
At a glance
- FDA status: sermorelin / Geref discontinued in 2008; approvals withdrawn effective June 18, 2009; no approved product today [2]
- FDA status: tesamorelin / Approved November 10, 2010 (BLA 022505); current labels Egrifta SV and Egrifta WR [4][5]
- Approved use: tesamorelin / Excess abdominal fat in HIV-infected adults with lipodystrophy only [5]
- Approved uses: Geref (sermorelin) / Pediatric idiopathic growth hormone deficiency and a pituitary diagnostic test, both withdrawn [2]
- Tesamorelin pivotal result / Visceral fat -15.2% vs +5.0% on placebo at 26 weeks (n=412) [1]
- Sermorelin trial result / Height velocity 4.1 to 8.0 cm/yr at 6 months in 86 evaluable children [3]
- Bottom line / Tesamorelin is the only one of the two with adult body-composition efficacy data [1][3]
What each peptide is and what it is approved to do
Sermorelin is a 29-amino-acid analogue of human growth hormone-releasing hormone (GHRH), the shortest synthetic peptide with the full biological activity of GHRH [6]. It acts on the pituitary GHRH receptor to make the body release its own growth hormone; it is not growth hormone [6]. After an intravenous dose in healthy men it was eliminated quickly, yet growth hormone stayed raised for about 3 hours [7].
Sermorelin acetate reached the US market as Geref under two applications: a 0.05 mg ampule approved December 28, 1990 for evaluating the pituitary's ability to secrete growth hormone, and 0.5 mg and 1 mg vials approved September 26, 1997 for treating idiopathic growth hormone deficiency in children with growth failure [2]. The manufacturer discontinued both products in 2008 and asked FDA to withdraw the applications; FDA withdrew both approvals effective June 18, 2009 [2]. In March 2013 FDA determined that Geref was not withdrawn from sale for reasons of safety or effectiveness [2]. No sermorelin product is FDA-approved today, so what is sold is compounded, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [8]. Geref was never approved for adults, anti-aging, weight loss or athletic performance [2].
Tesamorelin is the 44-amino-acid human growth hormone-releasing factor sequence with a hexenoyl group on the N-terminal tyrosine, molecular weight about 5135.9 Da [5]. FDA approved it on November 10, 2010 under BLA 022505 [4]. The current labels are Egrifta SV (2 mg vial) and Egrifta WR (11.6 mg vial) [5][9]. The only approved use is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, and the label attaches three limitations: long-term cardiovascular safety has not been established, the risk and benefit of continuing should be weighed in patients who have not had a reduction in visceral adipose tissue, and it is not indicated for weight loss management, its effect on weight being neutral [5].
Tesamorelin efficacy: what the trials measured
In the first pivotal trial, 412 HIV-infected adults with abdominal fat accumulation received tesamorelin 2 mg or placebo subcutaneously daily for 26 weeks [1]. Visceral adipose tissue on CT fell 15.2% on tesamorelin and rose 5.0% on placebo; triglycerides fell 50 mg/dL versus a 9 mg/dL rise; the total-to-HDL cholesterol ratio fell 0.31 versus a 0.21 rise; IGF-1 rose 81.0% versus a 5.0% fall, all with P<0.001 [1]. There were no significant glycemic differences between groups [1]. Expressed as absolute area, the Egrifta label reports visceral fat changes of -27 versus +4 cm2, a difference of -31 cm2 (95% CI -39 to -24) [5].
A second trial randomized 404 HIV-infected adults 2:1 to tesamorelin 2 mg or placebo daily [10]. At 6 months visceral fat fell 10.9% (-21 cm2) versus 0.6% (-1 cm2) on placebo (P<0.0001), with no change in glucose parameters [10]. In the extension, patients re-randomized to keep tesamorelin had about an 18% visceral fat reduction at 12 months, while the gain was rapidly lost in those switched to placebo [10]. The label reports the week 26 to week 52 visceral fat change as 0% to -5% on continued tesamorelin versus +16% to +22% on placebo [5].
A pooled analysis of the two phase 3 trials covered 806 patients (543 tesamorelin, 263 placebo) [11]. At week 26 visceral fat changed -24 versus +2 cm2, a treatment effect of -15.4%; triglycerides -37 versus +6 mg/dL; IGF-1 +108 versus -7 ng/mL; glucose differences were not clinically meaningful, and continuing tesamorelin to week 52 kept visceral fat down by 35 cm2 (-17.5%) [11].
A smaller trial randomized 50 HIV-infected men and women to tesamorelin 2 mg (n=28) or placebo (n=22) for 6 months [12]. Visceral fat changed -34 versus +8 cm2, a treatment effect of -42 cm2 (95% CI -71 to -14), and liver fat (lipid-to-water percentage) changed by a median -2.0% versus +0.9% (P=.003) [12]. A 12-month trial that enrolled 61 people with HIV and fatty liver found tesamorelin lowered liver fat by an absolute 4.1 percentage points more than placebo (95% CI -7.6 to -0.7), a 37% relative reduction, and 35% versus 4% reached liver fat below 5%; fatty liver is not an approved use [13].
Sermorelin efficacy: what the data actually show
The key sermorelin study enrolled 110 previously untreated prepubertal children with growth hormone deficiency in an open-label, multicenter, 1-year study of 30 micrograms/kg subcutaneously at bedtime; 86 children were evaluable for efficacy [3]. Mean height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months, and 74% were good responders at 6 months [3]. A review of sermorelin in children describes once-daily bedtime subcutaneous sermorelin 30 micrograms/kg as effective in some prepubertal children, with height-velocity gains sustained over 12 months [6].
The adult evidence is much thinner. In one study, 10 healthy men with a mean age of 68 took 0.5 mg and 1 mg of GHRH(1-29) subcutaneously twice daily for 14 days each in random order, and were compared with 9 young men of mean age 26 [14]. At the higher dose, 24-hour growth hormone and IGF-1 rose to levels not significantly different from the young men [14]. That was a short physiology study, not a trial of clinical benefit: it measured hormone levels rather than body composition or visceral fat [14].
Tesamorelin's efficacy data come from randomized, placebo-controlled adult trials with imaging endpoints; sermorelin's come from a pediatric growth trial and a 14-day adult hormone study.
How each is dosed
For tesamorelin, the Egrifta SV label describes a 1.4 mg once-daily subcutaneous dose and the Egrifta WR label describes 1.28 mg once daily; the two formulations differ in dose, vial strength, reconstitution and storage, and the labels state they are not substitutable [5][9]. The pivotal trials used 2 mg daily of the original 1 mg/vial product, and FDA accepted the SV 1.4 mg dose because its exposure (Cmax and AUC) is similar to that 2 mg dose [5].
Sermorelin has no current approved dose, since no sermorelin product is approved [2]. The doses used in studies were 30 micrograms/kg once daily subcutaneously at bedtime in children and 0.5 mg or 1 mg twice daily for 14 days in older men [3][14]. Neither is a recommended dose.
Safety and monitoring
On tesamorelin, the label asks for IGF-1 monitoring: among patients treated for 26 weeks, 47% had IGF-1 above 2 standard deviation scores and 36% above 3 SDS, and among those treated 52 weeks, 34% and 23% [5]. The effects of prolonged IGF-1 elevation are unknown, and the label says to consider discontinuation for persistent elevations, for example above 3 SDS, particularly when the fat-loss response is not robust [5]. Glucose is the other labeled concern: HbA1c of 6.5% or higher developed in 5% of tesamorelin patients versus 1% of placebo patients by week 26 (hazard ratio about 3.3, 95% CI 1.4 to 9.6), and the label says to evaluate glucose before starting treatment and during treatment [5].
Fluid retention (edema, joint pain, carpal tunnel syndrome), hypersensitivity reactions in 4% of trial patients, and injection-site reactions are labeled warnings [5]. Injection-site reactions occurred in 25% of tesamorelin patients versus 14% of placebo patients during the first 26 weeks [5]. The most common reactions, above 5%, were arthralgia, injection-site erythema, injection-site pruritus, pain in extremity, peripheral edema and myalgia; in the label's combined table, arthralgia was 13% versus 11% on placebo, peripheral edema 6% versus 2% and myalgia 6% versus 2% [5]. Tesamorelin is contraindicated with disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity and pregnancy; in rats, exposure at roughly 2 to 4 times the human dose produced hydrocephalus in offspring [5][9]. Safety and effectiveness in children are not established, and there is no information on use above age 65 [5].
For sermorelin, the safety data come from that open-label pediatric study: no adverse changes were seen in general biochemistry or hormone tests, fasting glucose did not change, IGF-I was not excessively raised, and sermorelin was well tolerated overall [3].
One point the two share: WADA's Prohibited List names both sermorelin and tesamorelin in S2.2.4, and both are prohibited at all times, in and out of competition [15][16].
Bottom line
For reducing visceral fat in adults with HIV-associated lipodystrophy, tesamorelin has randomized, placebo-controlled data and a labeled dose [1][11][5]. Sermorelin's main study was an open-label, multicenter study of growth in children with growth hormone deficiency, and its adult study measured hormone levels over 14 days, not fat or lean mass [3][14]. Sermorelin products in the United States today are compounded and are not FDA-approved [8].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Questions worth asking
Frequently asked questions
Is sermorelin or tesamorelin more effective?
Does sermorelin reduce belly fat?
What is the approved tesamorelin dose?
What dose of sermorelin was used in studies?
Is tesamorelin approved for weight loss or anti-aging?
What are the main risks of tesamorelin?
References
Show all 16 referencesHide references
- Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70.
- Federal Register :: Request Access.
- Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-96.
- Drugs@FDA: FDA-Approved Drugs.
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57.
- Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-5.
- Official web page.
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-22.
- Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-304.
- Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-9.
- Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830.
- Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-5.
- World Anti-Doping Agency.
- World Anti-Doping Agency.